An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination

Nature Communications

Volumn 7, Issue , 2016, Pages

  Keough, Michael B ^a   Rogers, James A ^a   Zhang, Ping ^b   Jensen, Samuel K ^a   Stephenson, Erin L ^a   Chen, Tieyu ^b   Hurlbert, Mitchel G ^a   Lau, Lorraine W ^a   Rawji, Khalil S ^a   Plemel, Jason R ^a   Koch, Marcus ^a   Ling, Chang Chun ^b   Yong, V Wee ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; AMINE; BENZATROPINE; CHONDROITIN SULFATE PROTEOGLYCAN INHIBITOR; CLEMASTINE; CLOBETASOL; FLUOROSAMINE; GLYCOPROTEIN; MICONAZOLE; NEUROCAN; PHOSPHACAN; PROTEIN SYNTHESIS INHIBITOR; QUETIAPINE; UNCLASSIFIED DRUG; VERSICAN; 4-FLUORO-N-ACETYLHEXOSAMINE URIDINE DIPHOSPHATE; GLUCOSAMINE; PROTEOCHONDROITIN SULFATE; URIDINE DIPHOSPHATE SUGAR;

CELLS AND CELL COMPONENTS; DIFFERENTIATION; DRUG; INHIBITOR; LESION; NERVOUS SYSTEM; NERVOUS SYSTEM DISORDER; PHENOTYPE; PROTEIN; SULFATE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL CULTURE; CELL GROWTH; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIA; PHENOTYPE; REMYELINIZATION; WESTERN BLOTTING; WHITE MATTER; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CARBOHYDRATE ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; METABOLISM; MOLECULAR LIBRARY; NEWBORN; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; STEM CELL;

MUS;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CARBOHYDRATE SEQUENCE; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; CHONDROITIN SULFATE PROTEOGLYCANS; FEMALE; GLUCOSAMINE; HUMANS; MICE, INBRED C57BL; MOLECULAR STRUCTURE; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; REMYELINATION; SMALL MOLECULE LIBRARIES; STEM CELLS; URIDINE DIPHOSPHATE SUGARS;

EID: 84964950501     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11312     Document Type: Article

References (50)

1. Patrikios, P. et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129, 3165-3172 (2006).
2. Patani, R., Balaratnam, M., Vora, A. & Reynolds, R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol. Appl. Neurobiol. 33, 277-287 (2007).
3. Goldschmidt, T., Antel, J., König, F. B., Brück, W. & Kuhlmann, T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72, 1914-1921 (2009).
4. Fünfschilling, U. et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485, 517-521 (2012).
5. Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487, 443-448 (2012).
6. Irvine, K. A. & Blakemore, W. F. Remyelination protects axons from demyelination-associated axon degeneration. Brain 131, 1464-1477 (2008).
7. Keough, M. B. & Yong, V. W. Remyelination therapy for multiple sclerosis. Neurotherapeutics 10, 44-54 (2013).
8. Hughes, E. G., Kang, S. H., Fukaya, M. & Bergles, D. E. Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. Nat. Neurosci. 16, 668-676 (2013).
9. Young, K. M. et al. Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling. Neuron 77, 873-885 (2013).
10. Kotter, M. R., Stadelmann, C. & Hartung, H.-P. Enhancing remyelination in disease-can we wrap it up? Brain 134, 1882-1900 (2011).
11. John, G. R. et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat. Med. 8, 1115-1121 (2002).
12. Fancy, S. P. J. et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 23, 1571-1585 (2009).
13. Williams, A., et al. Semaphorin 3A and 3F: Key players in myelin repair in multiple sclerosis? Brain 130, 2554-2565 (2007)
14. Syed, Y. A. et al. Inhibition of CNS remyelination by the presence of semaphorin 3A. J. Neurosci. 31, 3719-3728 (2011).
15. Mi, S. et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 13, 1228-1233 (2007).
16. Kotter, M. R., Li, W.-W., Zhao, C. & Franklin, R. J. M. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J. Neurosci. 26, 328-332 (2006).
17. Back, S. A. et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 11, 966-972 (2005).
18. Sloane, J. A. et al. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc. Natl Acad. Sci. USA 107, 11555-11560 (2010).
19. Lau, L. W. et al. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann. Neurol. 72, 419-432 (2012).
20. Lau, L. W., Cua, R., Keough, M. B., Haylock-Jacobs, S. & Yong, V. W. Pathophysiology of the brain extracellular matrix: A new target for remyelination. Nat. Rev. Neurosci. 14, 722-729 (2013).
21. Silver, J. & Miller, J. H. Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5, 146-156 (2004).
22. Bradbury, E. J. et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 416, 636-640 (2002).
23. Moon, L. D., Asher, R. A., Rhodes, K. E. & Fawcett, J. W. Regeneration of CNS axons back to their target following treatment of adult rat brain with chondroitinase ABC. Nat. Neurosci. 4, 465-466 (2001).
24. Laabs, T. L. et al. Inhibiting glycosaminoglycan chain polymerization decreases the inhibitory activity of astrocyte-derived chondroitin sulfate proteoglycans. J. Neurosci. 27, 14494-14501 (2007).
25. Lang, B. T. et al. Modulation of the proteoglycan receptor PTPs promotes recovery after spinal cord injury. Nature 518, 404-408 (2014).
26. Shen, Y. et al. PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science 326, 592-596 (2009).
27. Sobel, R. A. & Ahmed, A. S. White matter extracellular matrix chondroitin sulfate/dermatan sulfate proteoglycans in multiple sclerosis. J. Neuropathol. Exp. Neurol. 60, 1198-1207 (2001).
28. Siebert, J. R. & Osterhout, D. J. The inhibitory effects of chondroitin sulfate proteoglycans on oligodendrocytes. J. Neurochem. 119, 176-188 (2011).
29. Nigro, J. et al. Regulation of heparan sulfate and chondroitin sulfate glycosaminoglycan biosynthesis by 4-fluoro-glucosamine in murine airway smooth muscle cells. J. Biol. Chem. 284, 16832-16839 (2009).
30. Deshmukh, V. A. et al. A regenerative approach to the treatment of multiple sclerosis. Nature 502, 327-332 (2013).
31. Mei, F. et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat. Med. 20, 954-960 (2014).
32. Najm, F. J. et al. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo. Nature 522, 216-220 (2015).
33. Samanani, S. et al. Screening for inhibitors of microglia to reduce neuroinflammation. CNS Neurol. Disord. Drug Targets 12, 741-749 (2013).
34. Yu, P., Wang, H., Katagiri, Y. & Geller, H. M. An in vitro model of reactive astrogliosis and its effect on neuronal growth. Methods Mol. Biol. 814, 327-340 (2012).
35. Yi, J.-H. et al. Alterations in sulfated chondroitin glycosaminoglycans following controlled cortical impact injury in mice. J. Comp. Neurol. 520, 3295-3313 (2012).
36. Cua, R. C. et al. Overcoming neurite-inhibitory chondroitin sulfate proteoglycans in the astrocyte matrix. Glia 61, 972-984 (2013).
37. Keough, M. B., Jensen, S. K. & Yong, V. W. Experimental demyelination and remyelination of murine spinal cord by focal injection of lysolecithin. J. Vis. Exp. 97, doi:10.3791/52679 (2015).
38. Horii-Hayashi, N. et al. Localization of chondroitin sulfate proteoglycan versican in adult brain with special reference to large projection neurons. Cell Tissue Res. 334, 163-177 (2008).
39. Zhao, R.-R. & Fawcett, J. W. Combination treatment with chondroitinase ABC in spinal cord injury-breaking the barrier. Neurosci. Bull. 29, 477-483 (2013).
40. Barthel, S. R. et al. Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N-and O-glycans without direct incorporation. J. Biol. Chem. 286, 21717-21731 (2011).
41. Oh, L. Y. & Yong, V. W. Astrocytes promote process outgrowth by adult human oligodendrocytes in vitro through interaction between bFGF and astrocyte extracellular matrix. Glia 17, 237-253 (1996).
42. Grigorian, A. et al. N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis. J. Biol. Chem. 286, 40133-40141 (2011).
43. Gainers, M. E. et al. Skin-homing receptors on effector leukocytes are differentially sensitive to glyco-metabolic antagonism in allergic contact dermatitis. J. Immunol. 179, 8509-8518 (2007).
44. Wu, Y. et al. Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. Mol. Biol. Cell 15, 2093-2104 (2004).
45. Ruckh, J. M. et al. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell 10, 96-103 (2012).
46. O'Meara, R. W., Ryan, S. D., Colognato, H. & Kothary, R. Derivation of enriched oligodendrocyte cultures and oligodendrocyte/neuron myelinating co-cultures from post-natal murine tissues. J. Vis. Exp. 54, doi:10.3791/3324 (2011).
47. Medina-Rodríguez, E. M., Arenzana, F. J., Bribián, A. & de Castro, F. Protocol to isolate a large amount of functional oligodendrocyte precursor cells from the cerebral cortex of adult mice and humans. PLoS ONE 8, e81620 (2013).
48. Giuliani, F., Goodyer, C. G., Antel, J. P. & Yong, V. W. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 171, 368-379 (2003).
49. Massey, J. M. et al. Increased chondroitin sulfate proteoglycan expression in denervated brainstem targets following spinal cord injury creates a barrier to axonal regeneration overcome by chondroitinase ABC and neurotrophin-3. Exp. Neurol. 209, 426-445 (2008).
50. Giuliani, F. et al. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158, 213-221 (2005).